Tadalafil Tablet, Film Coated
Product Images NDC 71335-1884

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1884). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351884)

This is a drug label for Tadalafil 5mg tablets manufactured by Sun Pharmaceutical Industries Ltd. The tablets are yellow, oval-shaped, and come in a bottle containing 30 tablets. The storage recommendation is to keep the bottle at room temperature and away from the reach of children. The label includes information about the National Drug Code (NDC) and the expiration date but the date is not specified in this extract.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

This appears to be a chart displaying the standing and supine systolic blood pressure (in mmHg units) at different time intervals after taking either Tadalafil 20 mg and doxazosin 8 mg or a placebo and doxazosin 8 mg. No other information or context is available to provide further details.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

This appears to be a medical study about the effects of taking different doses and combinations of tadalafil and doxazosin on systolic blood pressure at different times after administration. Specifically, it looks like they measured the effects at 08:00 and 20:00.*

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

This is a graph that shows the concentration of plasma tadalafil in micrograms per liter (ug/L) over time (hours) after different doses of tadalafil administration. The doses include a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg doses for five consecutive days. The concentration of plasma tadalafil is plotted on the y-axis, while time is plotted on the x-axis. The graph shows that the concentration of plasma tadalafil reaches a peak approximately 2 hours after administration and then gradually decreases over time for all doses.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

This text presents a comparison between Tadalafil 5 mg and Placebo concerning the change from baseline in IPSS total score. The duration of treatment is not provided, and there is a significant difference between the two options (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

The text describes the change from the baseline in IPSS total score in patients who received Tadalafil 5 mg compared to Placebo, over a 12-week treatment period. The graph presented shows a significant decrease in IPSS total score from baseline with Tadalafil 5 mg compared to Placebo (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

This text provides information about the change in IPSS (International Prostate Symptom Score) total score due to treatment with Tadalafil 5 mg compared to a placebo. The text also indicates that the difference between the two treatments was statistically significant (p<0.01). However, no information is provided about the duration of the treatment.*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.